Showing results (81-90 of 112) with videos related to
Sort By:
Pageof 12
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|March 13, 2026
Long-term survival outcomes from a phase II trial of perioperative capecitabine plus oxaliplatin for advanced gastric cancer with extensive lymph node metastases: OGSG 1701Shunji Endo, Yutaka Kimura, Naotoshi Sugimoto, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 23, 2025
Randomized Phase III Trial of Ramucirumab Beyond Progression Plus Irinotecan in Patients With Ramucirumab-Refractory Advanced Gastric Cancer: RINDBeRG TrialDaisuke Sakai, Shigenori Kadowaki, Ryohei Kawabata, et al.JCO Precision Oncology|January 20, 2022
RAS Mutations in Circulating Tumor DNA and Clinical Outcomes of Rechallenge Treatment With Anti-EGFR Antibodies in Patients With Metastatic Colorectal CancerYu Sunakawa, Masato Nakamura, Masahiro Ishizaki, et al.Cancer Medicine|July 28, 2018
A prospective Phase II study to examine the relationship between quality of life and adverse events of first-line chemotherapy plus cetuximab in patients with KRAS wild-type unresectable metastatic colorectal cancer: QUACK trialShigeyoshi Iwamoto, Akira Ooki, Satoshi Morita, et al.Clinical Colorectal Cancer|November 17, 2019
A Phase II Study of Regorafenib With a Lower Starting Dose in Patients With Metastatic Colorectal Cancer: Exposure-Toxicity Analysis of Unbound Regorafenib and Its Active Metabolites (RESET Trial)Takeshi Suzuki, Yasutaka Sukawa, Chiyo K Imamura, et al.The Oncologist|September 12, 2020
Phase II Study of Panitumumab Monotherapy in Chemotherapy-Naïve Frail or Elderly Patients with Unresectable RAS Wild-Type Colorectal Cancer: OGSG 1602Tetsuji Terazawa, Takeshi Kato, Masahiro Goto, et al.Cancer Medicine|January 22, 2020
Patient-reported symptom burden as a prognostic factor in treatment with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trialAkira Ooki, Satoshi Morita, Shigeyoshi Iwamoto, et al.International Journal of Clinical Oncology|April 30, 2021
Safety and efficacy of panitumumab in combination with trifluridine/tipiracil for pre-treated patients with unresectable, metastatic colorectal cancer with wild-type RAS: The phase 1/2 APOLLON studyTakeshi Kato, Yoshinori Kagawa, Yasutoshi Kuboki, et al.BMC Cancer|June 28, 2022
Impact of early tumor shrinkage on quality of life in patients treated with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: results of Phase II QUACK trialAkira Ooki, Satoshi Morita, Akihito Tsuji, et al.Med (New York, N.Y.)|June 20, 2024
QUATTRO-II randomized trial: CAPOXIRI+bevacizumab vs. FOLFOXIRI+bevacizumab as first-line treatment in patients with mCRCHideaki Bando, Daisuke Kotani, Hironaga Satake, et al.Pageof 12